• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Iris Acquisition Corp filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8/26/24 4:01:27 PM ET
    $IRAA
    Blank Checks
    Finance
    Get the next $IRAA alert in real time by email
    false 0001831874 0001831874 2024-08-21 2024-08-21 0001831874 IRAAU:UnitMember 2024-08-21 2024-08-21 0001831874 us-gaap:CommonClassAMember 2024-08-21 2024-08-21 0001831874 us-gaap:WarrantMember 2024-08-21 2024-08-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported):  August 21, 2024

     

    IRIS ACQUISITION CORP

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40167   85-3901431
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    3rd Floor Zephyr House

    122 Mary Street, George Town

    PO Box 10085

    Grand Cayman KY1-1001, Cayman Islands

    (Address of principal executive offices) (Zip Code)  

     

    Registrant’s telephone number, including area code: 971 43966949

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each
    exchange on
    which registered
             
    Units, each consisting of one share of Class A Common Stock and one-fourth of one Redeemable Warrant   IRAAU   The Nasdaq Stock Market LLC
             
    Class A Common Stock, par value $0.0001 per share   IRAA   The Nasdaq Stock Market LLC
             
    Warrants, each exercisable for one share of Class A Common Stock $11.50 per share   IRAAW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    As previously reported, Iris Acquisition Corp (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company had failed to comply with Nasdaq Listing Rule IM-5101-2 (“Rule IM-5101-2”), which requires that a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its IPO registration statement (the “Nasdaq Deadline”). The Company submitted a request for a hearing with Nasdaq to appeal the delisting determination on March 12, 2024. On May 2, 2024, the Company received a written notice from the Listing Qualifications Department of Nasdaq, notifying the Company that because it no longer met the minimum 500,000 publicly held shares requirement for The Nasdaq Capital Market under Nasdaq Listing Rule 5810(d)(2), this deficiency was an additional basis for delisting and the Company would also need to address this deficiency at the Hearing. On May 21, 2024, the Company received a response from the Nasdaq Hearings Panel (the “Panel”) granting the Company’s request for continued listing on The Nasdaq Capital Market. The Company has until September 3, 2024, to demonstrate compliance with all applicable requirements for initial listing on The Nasdaq Global Market by the Company’s successor, Iris Parent Holding Corp.

     

    On August 21, 2024, the Company received a written notice (the “Notice”) from Nasdaq that pursuant to Nasdaq Listing Rule 5810(d)(2), the Company’s failure to timely file Form 10-Q for the quarter ended June 30, 2024 (the “Q2 2024 Form 10-Q”) by August 19, 2024 serves as an additional basis for delisting. On August 23, 2024, the Company filed the Q2 2024 Form 10-Q.

     

    Pursuant to the Notice, the Company must present its views with respect to this additional deficiency to the Panel in writing no later than August 28, 2024.

     

    The Company intends to present its views with respect to this additional deficiency to the Panel in writing no later than August 28, 2024.

     

    Forward Looking Statements

     

    Certain information contained in this report consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict. Words such as “will,” “would,” “may,” “intends,” “anticipates,” “potential,” and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. For example, there can be no assurance that Nasdaq will grant the Company any relief from delisting or that the Company can ultimately meet applicable Nasdaq requirements for any such relief, that the Company will regain compliance with the Nasdaq Listing Rules in the future, or otherwise meet Nasdaq compliance standards. The forward-looking statements contained in this report speak only as of the date of this report and the Company undertakes no obligation to publicly update any forward-looking statements to reflect changes in information, events or circumstances after the date of this report, unless required by law.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No   Description
    99.1   Press Release dated August 26, 2024
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      IRIS ACQUISITION CORP
    Dated: August 26, 2024  
         
      By: /s/ Sumit Mehta
        Name: Sumit Mehta
        Title: Chief Executive Officer

     

     

     

    Get the next $IRAA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRAA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IRAA
    SEC Filings

    View All

    SEC Form 15-12G filed by Iris Acquisition Corp

    15-12G - Iris Acquisition Corp (0001831874) (Filer)

    4/30/25 9:25:13 AM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form 10-K filed by Iris Acquisition Corp

    10-K - Iris Acquisition Corp (0001831874) (Filer)

    4/15/25 9:48:28 PM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form NT 10-K filed by Iris Acquisition Corp

    NT 10-K - Iris Acquisition Corp (0001831874) (Filer)

    3/31/25 4:01:42 PM ET
    $IRAA
    Blank Checks
    Finance

    $IRAA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Legion Partners Issues Letter to The Chefs' Warehouse, Inc. Shareholders Calling for Urgently Needed Board Change

    Highlights Company's Chronic Operational and Share Price Underperformance and the Need for New Skill Sets in the Boardroom to Help Chef Reach its Full Potential Nominates Four Highly Qualified, Independent Directors Who Would Bring Valuable Experience in Operations, Finance, Information Systems, Capital Allocation and Strategic Planning to the Board Legion Partners Asset Management, LLC, together with its affiliates (collectively, "we" or "Legion Partners"), is a significant shareholder of The Chefs' Warehouse, Inc. ("Chef", or the "Company") (NASDAQ:CHEF). Today, Legion Partners issued a public letter to the Company's shareholders announcing its nomination of four candidates to the Boa

    2/8/24 8:30:00 AM ET
    $AMPS
    $CHEF
    $F
    Electric Utilities: Central
    Utilities
    Food Distributors
    Consumer Discretionary

    Program CD47, provided the CMC service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp

    NEW YORK and LONDON, Dec. 5, 2022 /PRNewswire/ -- Recently, Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") (NASDAQ:IRAA), a publicly traded special purpose acquisition company ("SPAC") formed for the purpose of acquiring or merging with one or more businesses, announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed "Liminatus Pharma, Inc.". The combined company's common stock is expected to be listed on the Nasdaq Capital Market. The transaction funding includes commitments for a $15

    12/5/22 7:00:00 AM ET
    $IRAA
    Blank Checks
    Finance

    Liminatus Pharma LLC and Iris Acquisition Corp to combine to incorporate and accelerate much-needed cancer treatments

    Businesses announce Definitive Business Combination Agreement and plan to operate under Liminatus Pharma The transaction values the combined companies at a pro forma enterprise value of $334 million The immune-modulating cancer treatments being developed by Liminatus are a GCC Vaccine, GCC CAR-T therapy and a CD47 immune checkpoint inhibitor. The GCC vaccine and CAR-T patent portfolio originated from Thomas Jefferson University (TJU). The CD47 checkpoint inhibitor originates from a South Korean biotech company InnoBation Bio Co. Ltd. The transaction is expected to be completed in the first half of 2023 Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company develo

    11/30/22 8:46:00 PM ET
    $IRAA
    Blank Checks
    Finance

    $IRAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Saba Capital Management, L.P. sold $8,781,435 worth of shares (853,395 units at $10.29) (SEC Form 4)

    4 - Iris Acquisition Corp (0001831874) (Issuer)

    9/28/23 10:05:40 AM ET
    $IRAA
    Blank Checks
    Finance

    New insider Moore Capital Management, Lp claimed ownership of 100,000 shares (SEC Form 3)

    3 - Iris Acquisition Corp (0001831874) (Issuer)

    9/26/23 4:43:11 PM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form 3: New insider Saba Capital Management, L.P. claimed ownership of 853,395 shares

    3 - Iris Acquisition Corp (0001831874) (Issuer)

    2/23/23 1:13:50 PM ET
    $IRAA
    Blank Checks
    Finance

    $IRAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Iris Acquisition Corp (Amendment)

    SC 13G/A - Iris Acquisition Corp (0001831874) (Subject)

    2/14/24 5:28:26 PM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Iris Acquisition Corp (Amendment)

    SC 13G/A - Iris Acquisition Corp (0001831874) (Subject)

    2/13/24 5:52:28 PM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Iris Acquisition Corp (Amendment)

    SC 13G/A - Iris Acquisition Corp (0001831874) (Subject)

    9/27/23 11:10:24 AM ET
    $IRAA
    Blank Checks
    Finance